 Today I have the pleasure of speaking with Robert and Mike from Medex Health. How are you both today? Terrific. Thank you very much. Great. Yourself it. I am fantastic And we're gonna hit the ground running here with the big question which is many of the companies involved in telemedicine are currently seeing Substantial rallies and we're not really certain why Medex hasn't been the recipient of all of this goodwill So I'm not sure which of the two of you is best suited to answer this question. I Think Mike you probably have a better insight into that because quite honestly, I don't know why we have a terrific product We're rolling it out. It's a product for that age nobody should ever die from Skin cancer and fortunately people still do and we have Technology to solve that problem. I guess it's a failure on our part to get the message out appropriately Because we are you know driven with zeal and enthusiasm on the possibilities of our technology And what it can bring to our societies Mike What do you think? I think you've got a couple things at play here. I think the telemedicine Phenomenon was really started out in the US with teledoc that started to get a lot of traction COVID of course gave that a super boost because people didn't want to leave their you know They're hobbles they wanted to remain underground in bunkers and then but still be able to get medical care So what you've got what you got to see with that Tracy was this broad base ability to have a quick video With your doctor to a find out about where cova test and stations were if you had any other sort of normal Malices that people get from time to time flu the orates that sort of thing Medics in the tel is in the teledermatology space So we're sort of a specialized version of telemedicine and I think that's one of the reasons we haven't caught on yet The other thing is medics has been a little bit long in terms of our new platform And people have been waiting for us to become revenue show us the money kind of model And I think that that'll be that'll be something we'll speak about a little bit longer in this interview So I think that's a little bit about it, but I think we're very close now To getting a point where we'll be able to show investors that we do have traction and where we're deeply scalable And I think that's where you'll see the tide change for the company's share price in reviewing the markets over the years Of course Mike and Robert as you know, sometimes the good guys don't always get the attention that they deserve I've been in numerous meetings with you Mike where you have turned around and asked someone With regards to skin cancer and you pulled out your Psyoscopy and actually had a discussion with them about this. Is that not correct? Oh, yeah, I think anybody who knows me or travels with me is terrified that I'm gonna pull somebody over because I notice something I have normal on their skin that I want to talk to them about so yeah, I'm a little bit of a zealot that way for that I make no apologies. I personally have have caught 16 melanomas since I've been on this journey and so there's 16 people today that I know are safe and That gives me a lot of confidence in the technology and a lot of perseverance in terms of the goals Of course, it's part of our job to get the message out to the investor intel audience and widen your investment audience with what medics health is up to and speaking of that many of our investors myself included like to Invest in companies based on the CEOs and the jockeys that are leading the helm and in this last several months You've had some substantial changes in management Robert you're now the executive chairman and my congratulations. You're now the president Can you tell us how this might impact the company moving forward? I think what we saw is that there's a real need for all sort of resources to be focused on the rollout of the Dermsecure and Psyoscopy and we have assembled first of all Mike is a terrific leader and he's very very Familiar and very deeply committed to this technology So we have assembled a team under Mike which are a hundred percent focused on the rollout of Dermsecure so that the entire organization is focused on Dermsecure Psyoscopy and Ancillary technologies we can bring onto the Dermsecure platform Yeah, I would add to that as well. I think the biggest part for my point of view Is the focal points changed dramatically? Robert and I work hand-in-glove. We know each other from the past very well We get on quite well And so Robert on the operational side has a deep background and turnarounds a deep record of restructurings Robert has a fairly extensive background and and anybody clicks it clicks through to a site We'll see that from my perspective. This has been a you know a project of my heart and my and And and and a passionate drive of mine But you're only one person the latest rays We did allow us to complement the team and of course you always want to be able to hire people better more talented than you And just get out of the way and let them do their jobs and with our recent additions And we've got a few more about to announce here shortly I think people are gonna understand we're really being able to attract some pretty senior management team and On the sales side and for that I think that'll make some big differences in our revenue forecast coming down the road here Of course ongoing flow of news releases and achieving mandates as promised Let's just start if you don't mind with discussing when we might anticipate revenue from the Psioscopy deals Well, we're going to we don't do any forecasts and we don't do any forward-looking statements in that regard, but We do have revenue picking up in this quarter and we have announced that we anticipate this in the fourth Quarter we see the sales which were announced to Brazil that they're going to start taking off as well as Global initiatives we have in a number of European countries as well as We have some traction Coming in I'm chariot and in Canada which will start driving revenue. We feel very bullish about that And of course it's my understanding And I was reading about this this morning You're focused on skin cancer because of your unique imaging capability And is there a potential to actually expand this to additional platforms? Yeah, that's that's a okay. So that's a really good question What's our differentiation? There's other telemedicine platforms out there people have mobile phones They have other cameras none of those image capture devices We'll actually capture what medics is technology captures our ability to go two millimeters below the skin and catch a spectrophotometric views of the disorganization under the skin is Really our hallmark differentiation Dermatologists can read our technology the numbers look like this right now other competing technologies is what a 40% rejection rate on the image quality Dermatologists can't assess the patient when you're playing with something like skin cancer You don't want to be playing our technology It does not have a rejection rate because every image is absolutely perfect So the dermatologist when they click on ours knows that they're going to get the patient's going to get a complete assessment One of the things that came up was that they wanted additional image quality to be able to take distant imaging Which would include other things like psoriasis and acne and other skin maladies more of what they call inflammatory skin Issues and so medics has been working away on on as I think everybody knows another camera And we're expecting to release information about that very shortly And I think that'll make it again. It just adds more to the dermatological services It allows us to attract more dermatologists because we can you know, we can deal with more maladies of the skin and Again, of course that increases to the recurring revenue model So we're very very excited about being able to bring that to the market shortly We'll have more on that very shortly Just to add to that as well. We have a very highly qualified medical scientific advisory board and In developing our Dermsecure platform There are lead-in questions and information about the patient Which have been specifically designed by dermatologists both for the skin cancer research and other alternative Conditions that Mike just alluded to so they are dermatologists designed Questionnaires which form part of our telemedicine platform So that therefore that the expert who gets it the dermatologists can very quickly and time effectively assess What that patient's condition the surrounding area of the condition and if it's a mole or lesion which Is potentially cancerous add to that the Syroscopy imaging put that together. It's an extremely powerful and useful platform that can be deployed anywhere We don't often get to Have a conversation with both the executive chairman and the president of one of the companies that we are currently Covering so I'm going to put you both on the spot here for a second And I'm going to ask both of you to provide the number one reason why investors out there They're currently reviewing their portfolios and going why medics health and not one of the many other planes on the tarmac out there I'm going to start with you Mike What would you say the number one competitive advantage that medics health has presently and offers to potential new shareholders? Well, I think I think it's a great question if you look at our technology Everybody is sitting back. I think I'm waiting for us to come out of the woodwork with a fairly large Scale large-scale install where we announce a large-scale install when people start to understand that We have built a deeply scalable technology that is the best in the world I think we're going to start to get a lot different outlook from our shareholders If I looked at it from a market capitalization pricing model These other telemedicine companies are trading in the 7 800 900 million dollar range and we're in the 25 million dollar range So in terms of you know disequilibrium of pricing I would suggest for the risk associated with us I think we're a fairly good bet right here compared hopefully to some of the other telemedicine companies And of course Robert you have just made a decision with your own professional career, which is substantial I've enjoyed reviewing your Profile online. Can you tell me why you decided to become the executive chairman in what you deem the most competitive aspect? for medics health to maybe a new shareholder out there Well, I'll tell you about it. There's an emotional attachment as well Five people in my circle have had melanoma and recently in the last month a dear friend of mine passed away From complications from melanoma because 12 years ago a lesion on his leg was burnt off by a Practitioner and it turned out to have been melanoma which spreads throughout his body and he had a 12-year battle with the complications and melanoma the complications which come from melanoma and he finally passed away, so it isn't just a business Reason to but there's there's a reason nobody should ever die from cancer skin cancer and we have a technology that can solve that problem and So there's an emotional reason and there's also clearly believed that there's a strong business case and a Strong business model that can be built on this which will benefit all our shareholders Did I answer your question? Yes, absolutely Robert your answer? I think clearly articulates why more of us should not only be taking a look at medics health But actually reviewing information on skin cancer and skin cancer technology Would both of you entertain the notion of coming back and joining us and doing an Information only on skin cancer and more on medics health technology We'd be delighted to do that. Thank you truly absolutely Tracy and then thank you very much. Thank you both for joining us